Articles tagged with Sepsis
The Improving Pediatric Sepsis Outcomes Collaborative has received the prestigious John M. Eisenberg Award, recognizing outstanding leadership and innovation in reducing pediatric sepsis mortality. The award highlights programs demonstrating impact, innovation, sustainability, replicability, and data-driven success.
A large community-based study has found that individuals with type 2 diabetes are at a doubled risk of developing sepsis, particularly among younger adults and men. The study identified several modifiable risk factors, including smoking, high blood sugar, and complications of diabetes.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
Researchers discover vitamin B1 restores mitochondrial energy metabolism, drastically reducing lactate production and increasing survival rates in sepsis. The combination of vitamin B1 and glucose proves to be an effective treatment, promising hope for patients affected by this deadly condition.
The article highlights the need for improved sepsis diagnosis, personalized treatment, and innovative trial designs. It advocates for a multifaceted approach integrating timely diagnosis, tailored therapy, and equitable implementation to tackle the global burden of sepsis.
Researchers investigate the role of NUFIP1 in modulating dendritic cell activation during sepsis. They found that NUFIP1 facilitates dendritic cell function by mitigating excessive ER stress, leading to improved immune responses and survival outcomes in septic models.
The American College of Chest Physicians (CHEST) has launched a critical care APP education and certification program, covering 11 topic areas including patient-centered care and pharmacology. The CCAPP Certification Exam is now available, with an August 5 deadline to apply for the 2025 exam.
A new study has identified specific proteins in umbilical cord blood that signal acute systemic inflammation, providing a non-invasive means to diagnose early onset sepsis in preterm newborns. This discovery could lead to the development of a diagnostic test to avoid prolonged antibiotic exposure for infants at risk.
A large cohort study has shown that supplementary treatment with statins can boost survival chances for critically ill patients with sepsis. The results indicate a 39% lower death rate over 28 days after hospital admission.
A new study presents evidence that the Area Deprivation Index (ADI) is not an accurate measure of neighborhood health, particularly in areas with high costs of living. The Healthy Places Index (HPI), on the other hand, was found to be a better predictor of mortality risk for patients hospitalized with sepsis.
Researchers have reexamined the Ashwell-Morell receptor's functions using innovative glycoengineering techniques, clarifying its roles in sepsis and inflammation control. The study reveals that the receptor can bind to a specific type of protein glycan chain, which was previously thought to be incompatible with binding.
Researchers develop a novel self-assembling prodrug, LDO, that targets glycolysis and STING signaling to alleviate inflammation and improve survival in sepsis animal models. LDO reprograms macrophage polarization, reducing cytokine storms and acute lung injury.
Researchers from Radboud University Medical Center found that an existing drug can revive immune cells paralyzed by sepsis, a leading cause of death in ICUs. The study provides new perspectives for the treatment of sepsis and may lead to potential treatments for patients with immune paralysis.
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed in Elsevier's Scopus database. This achievement is a testament to the high-quality research published in these journals, which provide open access content in pulmonary and critical care medicine.
Preet Chaudhary and Michael Selsted, USC innovators, recognized by the National Academy of Inventors for their work on harnessing the power of the immune system. Their research aims to develop new treatments for diseases such as cancer, rheumatoid arthritis, and sepsis.
Researchers developed an AI-driven model to predict mortality risk in sepsis patients, outperforming traditional scoring systems. The model provides real-time risk alerts and enhances personalized interventions, leading to improved patient outcomes.
Researchers found that patients who received non-compliant care had more complex medical conditions and were more likely to present with unusual symptoms. The study's findings challenge the assumption that SEP-1 compliant care is associated with better survival, highlighting the need for risk-adjusted outcome measures.
This study investigated the effects of Shenfu Decoction on neutrophil chemotactic function in septic mice. The results showed that Shenfu Decoction improved neutrophil chemotaxis function, decreased P2X1 receptor expression, and increased CXCR1 and CXCR2 receptor expression.
Researchers studied how bacteria like Klebsiella pneumoniae cause systemic infection by tracking its movement in mouse models using a barcoding system. They found that bacteria can spread through two routes: metastatic dissemination and direct dissemination, with the former correlating to a stronger infection.
Thousands of Medicare beneficiaries developed postoperative infections up to six months after coronary artery bypass grafting or aortic valve replacement. Women had a 60% greater odds of developing infections, including urinary tract, pneumonia, and sepsis.
A systematic review found no moderate-to-high level evidence that compliance with the Centers for Medicare & Medicaid Services' (CMS) Severe Sepsis and Septic Shock Management Bundle was associated with improved sepsis mortality. The study suggests reconsidering the inclusion of the bundle in the Hospital Value-Based Purchasing program.
Researchers at Salk Institute discover SSRIs like Prozac regulate immune response, preventing sepsis in mice. The findings suggest a potential new use for the popular drug, which could lead to life-saving treatments and enhanced global preparedness for pandemics.
The new center aims to advance understanding, prevention, and management of sepsis through innovative research. Dr. Chanu Rhee and Dr. Michael Klompas will lead the effort, building on their expertise in sepsis surveillance, prevention, treatment, and policy.
Researchers propose systems immunology to tackle sepsis, identifying early warning signs and potential subtypes, which can lead to improved diagnostics and treatment. Targeted funding is urgently needed to develop large-scale omics studies and translate these insights into clinical results.
Researchers discovered that cells caught up in sepsis send out messages to other cells, causing them to die and fueling the spiraling inflammation. By understanding this process, scientists may be able to develop a treatment for inflammatory diseases like sepsis.
A recent study found a significant increase in long-term nursing home stay or death among older adults hospitalized with sepsis during the COVID-19 pandemic. The results suggest that all individuals, regardless of race and ethnicity, experienced increased mortality rates compared to before the pandemic.
A new study from the Salk Institute has discovered that a protein called BCL6 plays a crucial role in maintaining healthy muscle mass. Increasing BCL6 levels successfully reversed muscle losses in mice, suggesting that pairing GLP-1 medications with a BCL6-boosting drug could help counteract unwanted muscle loss.
This study identifies H3K14 lactylation as a crucial regulator of endothelial activation during sepsis-induced ARDS, driving ferroptosis and vascular injury. Inhibition of lactate production alleviated EC activation and improved survival rates in septic mice.
John Howington, MD, MBA, FCCP, is the new President of CHEST, succeeding Neil S. Freedman, who will be President-Elect in 2026. Dr. Howington has extensive leadership experience and has published over 49 research publications.
A nationwide cross-sectional study found sepsis incidence and mortality rates among hospitalized non-child cancer patients in China rose significantly, with higher rates observed in older patients.
New research reveals racial differences in mortality rates, with Black newborns facing higher risks of necrotizing enterocolitis and late-onset sepsis. Addressing social determinants of health is critical for promoting health equity in hospital outcomes.
A study published in JAMA found that electronic sepsis screening among hospitalized ward patients resulted in lower in-hospital 90-day mortality compared to no screening. The study also showed a significant reduction in mortality rates.
A study published in JAMA found that biomarker-guided antibiotic duration reduced in hospitalized patients with suspected sepsis. However, a daily C-reactive protein-guided protocol did not demonstrate significant benefits. The results suggest that procalcitonin-guided protocols may be a more effective approach.
Researchers have developed a non-invasive strategy that assesses blood flow through skeletal muscle to detect early signs of sepsis. The technique, combining hyperspectral near-infrared spectroscopy and diffuse correlation spectroscopy, was tested in rodents and detected sepsis before vital organs were affected.
Researchers found that HNL Dimer levels decrease rapidly within a day of successful antibiotic treatment, offering a time-saving advantage over traditional biomarkers. This study confirms the previous promising results and provides valuable insights for early diagnosis and treatment of sepsis.
Researchers have identified a genetic signature that can predict neonatal sepsis in newborns before symptoms appear, allowing for earlier recognition and life-saving treatment. The discovery has the potential to improve healthcare outcomes in lower- and middle-income countries where neonatal sepsis is most prevalent.
A cross-sectional study found that as hospital COVID-19 burdens increased, older racial and ethnic minority adults were more likely to die or experience major morbidity. The adverse outcomes were greater in magnitude among minority populations compared to white individuals.
Researchers found that certain factors increased the risk of death after sepsis, including advanced age, dementia, heart disease, cancer, and previous hospitalizations. A total of 50.6% of patients with sepsis died within two years, highlighting the need for closer monitoring and follow-up care.
A new study uncovers how different people respond to sepsis based on their genetic makeup, which could help identify who would benefit from certain treatments. The research found two groups of patients with opposite immune responses and identified the genetic regulators involved.
Researchers have gained insight into how a deadly strain of salmonella adapts to invasion, flourishing in hostile environments and evading immune defenses. The study sheds light on the role of fluid shear forces in bacterial behavior, which may accelerate the design of new therapies for life-threatening infections.
Prolonged β-lactam antibiotic infusions associated with reduced 90-day mortality in adults with sepsis or septic shock. This standard of care approach is now supported by high certainty evidence.
The BLING III trial found a 2% lower 90-day mortality and a 6% higher clinical cure rate for continuous β-lactam antibiotic infusions compared to intermittent infusions in critically ill patients with sepsis. Continuous infusions were also associated with improved patient outcomes.
Researchers have identified a distinct clinical pattern, PHES, that may respond better to targeted treatments in children with sepsis. This pattern is characterized by persistent hypoxemia, encephalopathy, and shock, and overlaps with biomarkers of inflammation and endothelial activity.
Scientists at Salk Institute discover a molecular mechanism that helps macrophages mount a coordinated response tailored to a specific immune challenge. The discovery reveals new immune system mechanisms that could be targeted with therapeutics to regulate inflammation.
A Boston University study suggests that in-hospital mortality for patients with sepsis may not accurately reflect true short-term mortality rates, potentially harming safety-net hospitals. The researchers found no difference in 30-day mortality between safety-net and non-safety-net hospitals, contrary to previous reports.
A study found that statin therapy significantly reduces the risk of cardiovascular disease (CVD) and all-cause mortality in adults aged 60 years and older, including those over 85. Statins also did not increase the risk for adverse events such as myopathies and liver dysfunction.
A nationwide study found a high incidence rate of sepsis cases among non-child cancer patients in China, with males exhibiting higher rates than females. The study also revealed significant geographic variations in sepsis burden across China, with regions having lower and higher development levels exhibiting elevated rates.
A clinical trial found that intravenous acetaminophen reduced the risk of organ injury and acute respiratory distress syndrome in sepsis patients. The therapy gave the greatest benefit to those most at risk for organ damage, showing a slight decrease in mortality.
A recent study found that treatment with intravenous acetaminophen for 5 days in critically ill sepsis patients was safe, but did not improve the primary end point of days alive and free of organ support. The study suggests acetaminophen may have a role in preventing or treating organ dysfunction in sepsis.
Researchers review cell-based therapies for comprehensive sepsis management, highlighting the potential of mesenchymal stem cells and innate immune cells like macrophages. The review also emphasizes the need for further studies on optimal dosage, administration routes, and storage methods to maximize efficacy and safety.
A new study found that treatment with piperacillin/tazobactam increased 90-day mortality by 5% compared to cefepime. The antibiotic depletes the gut microbiome, which plays a crucial role in metabolism, immunity, and preventing infections.
A Swedish study published in JAMA Network Open found that over one million newborns were given unnecessary antibiotics for suspected sepsis despite a reduction in sepsis cases. The researchers argue that the treatment burden is too high, suggesting potential to reduce antibiotic use.
Researchers analyzed blood stem cells in mice with prior sepsis and found they were fully recovered but failed to respond to a second inflammatory stimulus, leading to inefficient immune cell production.
A new study suggests that many cases of neonatal neutropenia may originate from suppression of fetal blood-forming stem cells by maternal interleukin 10. This immune deficiency greatly increases a newborn's susceptibility to infection, leading to serious health complications and even death.
Researchers discovered a DNA shift in innate immune memory cells that contributes to severe immune conditions like sepsis. By blocking this change, therapeutic interventions can restore normal monocyte activity, offering new hope for treating such conditions.
The study found that patient outcomes for six critical conditions worsened at urban hospitals, while rural hospitals experienced smaller declines, highlighting the need for tailored strategies to reduce excess deaths in future crises.
A new method uses digital DNA melting analysis to detect pathogens in blood samples, producing results in under six hours and reducing false positives compared to traditional blood cultures. This technology has the potential to save lives by accurately diagnosing sepsis, a leading cause of death worldwide.
A new analysis method for detecting bacteria in blood has been confirmed to provide accurate and fast results at smaller hospitals, enabling quicker antibiotic treatment. The test revealed a significant reduction in unnecessary antibiotic use and an improved patient outcome in one out of four cases.
An international research team developed a novel scoring system, called the Phoenix Sepsis Score, to diagnose sepsis in children. The scoring system enables physicians to quickly determine the severity of organ failure, leading to improved outcomes for affected children.
Researchers developed an AI algorithm to monitor patient variables and predict sepsis before symptom onset. The tool resulted in a 17% reduction in mortality rates.